-
Innovation Ranking
NewInnovation Ranking – Actinium Pharmaceuticals Inc
Actinium Pharmaceuticals Inc (Actinium) develops antibody radiation conjugates (ARC), which combine the targeting ability of antibodies with the cell killing ability of radiation. The company's pipeline products include Iomab-B for hematopoietic stem cell transplantation, Iomab-ACT for the treatment of GeneTx and Cell therapy conditioning, Actimab-A(CD33) for the treatment of relapsed/refractory AML. The three variants of Actimab-A developed by company are- Actimab-A (CD33) and CLAG-M; Actimab-A (CD33) and Venetoclax and Actimab-A (CD33) and Venetoclax with HMA. The company also offers AWE...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FPI-1434 in Ewing Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FPI-1434 in Ewing Sarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FPI-1434 in Ewing Sarcoma Drug Details: FP1-1434 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Actimab-A in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Actimab-A in Refractory Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Actimab-A in Refractory Acute Myeloid Leukemia Drug Details: Actimab-A (HuM195-Ac-225)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Actimab-A in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Actimab-A in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Actimab-A in Relapsed Acute Myeloid Leukemia Drug Details: Actimab-A (HuM195-Ac-225)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FPI-2068 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FPI-2068 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FPI-2068 in Solid Tumor Drug Details: FPI-2068 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FPI-2068 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FPI-2068 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FPI-2068 in Non-Small Cell Lung Cancer Drug Details: FPI-2068...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FPI-2068 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FPI-2068 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FPI-2068 in Pancreatic Ductal Adenocarcinoma Drug Details: FPI-2068 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FPI-2068 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FPI-2068 in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FPI-2068 in Metastatic Colorectal Cancer Drug Details: FPI-2068 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FPI-2068 in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FPI-2068 in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FPI-2068 in Head And Neck Squamous...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FPI-1434 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FPI-1434 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FPI-1434 in Solid Tumor Drug Details: FP1-1434 is under development for...